Nabla Bio
Latest round
- Series C
Last raised
- Jun 2025
Total raised
- $151M
Investors
- 13
About Nabla Bio
Established in 2020 and based in Massachusetts, US, Nabla Bio, Inc. develops an AI-first protein design platform to generate therapeutic antibodies. In July 2025, Nabla Bio, Inc. As of December 2021, co-founder Surge Biswas is the CEO of Nabla Bio, Inc. Nabla Bio, Inc. provides an AI-first protein design platform that enables rapid engineering of antibody therapeutics. The company’s platform combines state-of-the-art protein language modeling, a branch of AI-driven protein modeling with a novel high-throughput multiplex antibody assay technology to make new medicines and improve nutrition.
Who invested in Nabla Bio
13 investors across 5 rounds
See all investors in Nabla Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Nabla Bio
Who invested in Nabla Bio?
Nabla Bio has 13 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Nabla Bio raised?
Nabla Bio has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Nabla Bio last raise money?
Nabla Bio's most recent round on record is a Series C, in Jun 2025.
What does Nabla Bio do?
Established in 2020 and based in Massachusetts, US, Nabla Bio, Inc.
Where is Nabla Bio headquartered?
Nabla Bio is headquartered in Cambridge, US.
Which VCs invest in companies like Nabla Bio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Nabla Bio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Nabla Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.